

## 1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

**Product Name:** Omnipaque®

**Synonyms:** Omnipaque® 140 mg I/ml, 180 mg I/ml, 210 mg I/ml, 240 mg I/ml, 300mg/ml and 350 mg I/ml Injection

**Applications:** Radiodiagnostic

**Emergency Number:** In an emergency, call 1-800-654-0118

**Manufacturer:** Amersham Health  
101 Carnegie Center  
Princeton, NJ 08540-9998  
609-514-6000 or 1-800-654-0118

## 2. COMPOSITION/INFORMATION ON INGREDIENTS

<u>Ingredient Name</u>	<u>CAS No.</u>	<u>Percent by Weight</u>
Iohexol*	66108-95-0	> 25.0
Water	7732-18-5	> 25.0

\* - Sterling Health Protection Guide:  
5mg/m<sup>3</sup> 8-hr TWA, 10mg/m<sup>3</sup> STEL

## 3. HAZARDS IDENTIFICATION

\*\*\*\*\* **EMERGENCY OVERVIEW** \*\*\*\*\*

An aqueous solution. Presents little or no hazard if spilled or in fire.

\*\*\*\*\*

**WARNING:** This is a pharmaceutical material available only with a prescription - use only as directed. Persons allergic to shellfish or iodine may be allergic to iohexol.

## 4. FIRST AID MEASURES

**Eyes:** In case of eye contact, flush eyes with plenty of water for at least 15 minutes. Seek medical attention if irritation develops.

**Skin:** Wash thoroughly with soap and water.

**Ingestion:** In case of overdosage, seek immediate medical attention or contact the Poison Control Center for further instructions.

**Inhalation:** Not an expected route of entry.

## 5. FIRE FIGHTING MEASURES

**Flammable Properties:** Nonflammable. This is an aqueous-based formulation.

**Extinguishing Media:** Use any extinguishing agent which is suitable for the surrounding fire.

**Fire Fighting Procedures:** Use normal fire fighting gear. Ventilate area - free flame may rupture container and decompose product to form toxic and irritating iodine vapors.

**Unusual Fire and Explosion Hazards:** None known

## **6. ACCIDENTAL RELEASE MEASURES**

**Spills:** Contain the spill by placing paper towels or a suitable absorbent material around the edges of the spill and work inward. Carefully scoop up into a properly labeled waste container for disposal. Wash area of spill to remove from surfaces.

## **7. HANDLING AND STORAGE**

**Handling and Storage Precautions:** Store away from heat and light - these conditions may produce iodine vapors. Keep this and all drugs out of the reach of children.

**Work/Hygienic Practices:** Use good personal hygiene - wash hands and exposed skin thoroughly with soap and water after use.

## **8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

**Engineering controls:** Normal ventilation

**Eye/Face Protection:** None normally required. Avoid eye contact.

**Skin Protection:** None normally required. Gloves should be worn to clean up spills.

**Respiratory Protection:** None normally required.

## **9. PHYSICAL AND CHEMICAL PROPERTIES**

**Appearance:** Clear liquid

**Color:** Colorless to pale yellow

**Solubility in Water:** Soluble

**Specific Gravity:** Not applicable

## 10. STABILITY AND REACTIVITY

**Stability:** Stable

**Conditions to Avoid:** Exposure to flame or temperatures above 300 °F.

**Materials to Avoid:** None known

### Hazardous Decomposition

**Products:** Iodine vapors

### Hazardous

**Polymerization:** Will not occur

## 11. TOXICOLOGICAL INFORMATION

### Subchronic (Target

**Organ Effects):** The following adverse reactions have been reported:

**Central Nervous System:** Vertigo (including dizziness and lightheadedness), pain, vision abnormalities (including blurred vision and photomas), headache, and taste perversion. Other including anxiety, fever, motor and speech dysfunction, convulsion, paresthesia, somnolence, stiff neck, hemiparesis, syncope, shivering, transient ischemic attack, cerebral infarction, and nystagmus were reported.

**Gastrointestinal System:** Nausea and vomiting. Others including diarrhea, dyspepsia, cramp, and dry mouth were reported.

**Cardiovascular System:** Arrhythmias including PVCs and PACs, angina/chest, pain and hypotension. Others including cardiac failure, asystole, bradycardia, tachycardia, and vasovagal reaction were reported. In controlled clinical trials, involving 1485 patients, one fatality occurred. A cause and effect relationship between this death and iohexol has not been established.

**Respiratory System:** Dyspnea, rhinitis, coughing, and laryngitis.

**Skin and Appendages:** Urticaria, purpura, abscess, and pruritus.

**Carcinogenicity:** NTP: No, IARC: No, OSHA: No.

## 12. ECOLOGICAL INFORMATION

No data available

## 13. DISPOSAL CONSIDERATIONS

**Disposal Methods:** As of the MSDS revision date, this product does not meet the United States EPA definition of a hazardous waste. Dispose in accordance with local, state and federal regulations.

#### **14. TRANSPORT INFORMATION**

**Proper Shipping Name:** Non-regulated

#### **15. REGULATORY INFORMATION**

**U. S. Federal Regulations:**

This product does **not** contain any ingredients which are regulated on the U.S. EPA List of Toxic Chemicals (40 CFR 372) above the deminimus threshold, and is therefore not subject to release reporting under Section 313 of EPCRA.

#### **16. OTHER INFORMATION**

**Revision Date:** April 2003 (company name and emergency number)

**Reference**

**Documentation:** Primary references used in the preparation of this document:

1. Omnipaque® Package Insert
2. Omnipaque® MSDS (Sterling Winthrop)
3. ACGIH Guide to Occupational Exposure Values - 1991
4. Sterling Winthrop Corporate Quality Pharmaceutical File - 2/10/89

**Disclaimer:**

This information is furnished without warranty, representation, or license of any kind, except that it is accurate to the best of Amersham Health knowledge or obtained from sources believed to be accurate. Amersham Health does not assume any legal responsibility for use or reliance upon same. Customers are encouraged to conduct their own tests. Before using any product, read its label.